A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis

NCT07549984 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: IBI3033
DRUG: Placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.